Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Clinical and toxicological aspects of the antineoplastic drug cladribine: A review

  • 71 Accesses

  • 27 Citations

Summary

Cladribine (2-chlorodeoxyadenosine, 2-CdA) is a new antineoplastic drug which exerts its antilymphoproliferative activity by its resistance to the enzyme adenosine deaminase. Cladribine is mostly administered as a 7-day continuous infusion and in a dose of 0.1 mg/kg/day. However, preliminary data show that the subcutaneous and oral routes of administration might be feasible. The drug is well tolerated, and myelosuppression was found to be the dose-limiting toxicity. Nonhematological toxicity, such as alopecia, nausea, vomiting, stomatitis, diarrhea, and organ toxicity is mild or absent. Cladribine has shown efficacy in phase-II studies in hairy cell leukemia [response rate (RR)=75–100% and complete response rate (CR)=46–92%], chronic lymphocytic leukemia (RR=37–67% and CR=4–39%), and lymphocytic lymphoma (RR=43–52% and CR=14–20%). Furthermore, there is preliminary evidence that cladribine might be effective in the treatment of cutaneous T cell lymphoma (RR=47% and CR=20%), acute myeloid leukemia in children (RR=59% and CR=47%), acute lymphoid leukemia in children (RR=14% and CR=14%) and Waldenström macroglobulinemia (RR=58% and CR=3.5%). In multiple myeloma cladribine was not effective. Comparative randomized studies with established first-line and second-line therapeutic regimens are warranted and will define the ultimate place of cladribine in the therapy of malignant hematological disorders.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Giblett ER, Anderson JE, Cohen F, Pollaro B, Meuwissen HJ (1972) Adenosine deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 2:1067

  2. 2.

    Lauria F (1992) 2-Chlorodeoxyadenosine, a novel agent in the treatment of both lymphoid and myeloid malignancies. Haematologica (Pavia) 77:443

  3. 3.

    Cheson BD (1992) The purine analogs, a therapeutic beauty contest. J Clin Oncol 10:868

  4. 4.

    Carson DA, Wasson DB, Kaye J, Ullman B, Martin DW, Robins RK, Montgomery JA (1980) Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci USA 77:6865

  5. 5.

    Kazimierczuk Z, Cottam HB, Ravankar GR, Robins RK (1984) Synthesis of 2′-deoxytubercidin, 2′-deoxyadenosine and related 2′-deoxynucleosides via a novel direct stereospecific serum salt glycosylation procedure. J Am Med Soc 106:6379

  6. 6.

    Kizaki H, Shimada H, Ohsaka F, Sakurada T (1988) Adenosine, deoxyadenosine, and deoxyguanosine induce DNA cleavage in mouse thymocytes. J Immunol 141:1652

  7. 7.

    Carson DA, Wasson DB, Esparzo LM, Carrera CJ, Kipps TJ, Cottam HB (1992) Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine. Proc Natl Acad Sci USA 89:2970

  8. 8.

    Piro LD (1992) 2-Chlorodeoxyadenosine: drug development priorities. J Clin Oncol 10:1507

  9. 9.

    Saven A, Kawasaki H, Carrera CJ, Waltz T, Copeland B, Zyroff J, Kosty M, Carson DA, Beutler E, Piro LD (1993) 2-Chlorodeoxyadenosine dose escalation in nonhematologic malignancies. J Clin Oncol 11:671

  10. 10.

    Castaigne S (1993) 2-Chlorodeoxyadenosine in haematological malignancies. Nouv Rev Fr Hematol 35:13

  11. 11.

    Piro LD (1992) 2-Chlorodeoxyadenosine treatment of lymphoid malignancies. Blood 79:843

  12. 12.

    Saven A, Piro LD (1993) 2-Chlorodeoxyadenosine: a new nucleoside agent effective in the treatment of lymphoid malignancies. Leuk Lymph 10 [Suppl]:43

  13. 13.

    Beutler E (1992) Cladribine (2-Chlorodeoxyadenosine). Lancet 340:952

  14. 14.

    Baltz JK, Montello MJ (1993) Cladribine for the treatment of hematologic malignancies. Clin Pharm 12:805

  15. 15.

    Cheson BD (1992) New antimetabolites in the treatment of human malignancies. Semin Oncol 19:695

  16. 16.

    Bryson HM, Sorkin EM (1993) Cladribine, a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies. Drugs 46:872

  17. 17.

    Petzer AL, Bilgeri R, Zilian U, Haun M, Geisen FH, Pragnell I, Braunsteiner H, Konwalinka G (1991) Inhibitory effect of 2-chlorodeoxyadenosine on granulocytic, erythroid, and Tlymphocytic colony growth. Blood 78:2583

  18. 18.

    Liliemark J, Luliusson G (1991) On the pharmacokinetics of 2-chloro-2′-deoxyadenosine in humans. Cancer Res 51:5570

  19. 19.

    Spielberger RT, Larson RA, O'Brien SM, Williams SF, Ratain MJ (1993) Phase I study of 2-Chlorodeoxyadenosine (CdA) by 1 hour bolus infusion in hematologic malignancies. Proc ASCO 12:359

  20. 20.

    Liliemark J, Albertioni F, Hassan M, Juliusson G (1992) On the bioavailability of oral and subcutaneous 2-chloro-2′-deoxyadenosine in humans: alternative routes of administration. J Clin Oncol 10:1514

  21. 21.

    Albertioni F, Juliusson G, Liliemark J (1993) On the bioavailabilty of 2-chloro-2′-deoxyadenosine (CdA). The influence of food and omeprazole. Eur J Clin Pharmacol 44:579

  22. 22.

    Juliusson G, Liliemark J (1993) Complete remission of B-cell chronic lymphocytic leukaemia after oral cladribine. Lancet 341:54

  23. 23.

    Carson DA, Wasson DB, Beutler E (1984) Antileukemic and immunosuppressive activity of 2-chloro-2′-deoxyadenosine. Proc Natl Acad Sci USA 81:2232

  24. 24.

    Liliemark J, Pettersson B, Juliusson G (1991) Determination of 2-chloro-2′-deoxyadenosine in human plasma. Biomed Chrom 5:262

  25. 25.

    Santana VM, Mirro J, Kearns C, Schell MJ, Crom W, Blakley RL (1992) 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol 10:364

  26. 26.

    Santana VM, Mirro J, Harwood FC, Cherrie J, Schell M, Kalwinsky D, Blakley RL (1991) A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. J Clin Oncol 9:416

  27. 27.

    Weiss G, Kuhn J, Irvin R, Hardy J, Mooneyham T, Burris H, Eckardt J, Kalter S, Rodriguez G, Rothenberg M, Von Hoff D (1993) Phase I trial of 2-chlorodeoxyadenosine (2-CDA) by 120-hour infusion for solid cancers. Proc ASCO 12:455

  28. 28.

    Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD (1992) 2-Chlorodeoxyadenosine: an active agent in the treatment of cutanueous T-cell lymphoma. Blood 80:587

  29. 29.

    Saven A, Piro LD (1993) Complete remissions in hairy cell leukemia with 2-chlorodeoxyadenosine after failure with 2′-deoxycoformycin. Ann Intern Med 119:278

  30. 30.

    Tallman MS, Hakimian D, Variakojis D, Koslow D, Sisney GA, Rademaker AW, Rose E, Kaul K (1992) A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood 80:2203

  31. 31.

    Kay AC, Saven A, Carrera CJ, Carson DA, Thurston D, Beutler E, Piro LD (1992) 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J Clin Oncol 10:371

  32. 32.

    Estey EH, Kurzrock R, Kantarjian HM, O'Brien SM, McCredie KB, Beran M, Koller C, Keating MJ, Hirsch-Ginsberg C, Huh YO, Stass S, Freireich EJ (1992) Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood 79:882

  33. 33.

    Juliusson G, Liliemark J (1993) High complete remission rate from 2-chloro-2′-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocytic count. J Clin Oncol 11:679

  34. 34.

    Juliusson G, Liliemark J (1992) Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2′-deoxyadenosine (CdA): relation to opportunistic infections. Blood 79:888

  35. 35.

    Piro LD, Carrera CJ, Carson DA, Beutler E (1990) Lasting remissions in hairy-cell leukemia by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 322:1117

  36. 36.

    Sorensen JM, Vena DA, Montello MJ, Christian MC, Cheson BD (1993) Treatment of hairy cell leukemia (HCL) with 2-chlorodeoxyadenosine (CDA) under the group C protocol mechanism. Proc ASCO 12:988

  37. 37.

    Beutler E, Piro LD, Saven A, Kay AC, McMillan R, Longmire R, Carrera CJ, Morin P, Carson DA (1991) 2-Chlorodeoxyadenosine (2-CdA): a potent chemotherapeutic and immunosuppresive nucleoside. Leuk Lymphoma 5:1

  38. 38.

    Hakimian D, Tallman MS, Kiley C, Peterson L (1993) Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chlorodeoxyadenosine for hairy cell leukemia. Blood 82:1798

  39. 39.

    Jaiyesimi AI, Kantarjian HM, Estey EH (1993) Advances in therapy for hairy cell leukemia. Cancer 72:5

  40. 40.

    Keating MJ (1993) Chronic lymphoproliferative disorders: chronic lymphocytic leukemia and hairy-cell leukemia. Curr Op Oncol 5:35

  41. 41.

    Saven A, Piro LD, Carrera CJ, Carson DA, Beutler E. (1993) Hairy cell leukemia: new understanding of biology and treatment. In: Freireich EJ, Kantarjian H (eds) Leukemia: advances in research and treatment. Kluwer Academic, Dordrecht, pp 15–34

  42. 42.

    Saven A. Piro LD (1993) 2-Chlorodeoxyadenosine in the treatment of hairy cell leukemia. Cancer Invest 11:559

  43. 43.

    Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD (1991) 2-Chlorodeoxyadenosine treatment of chronic lymphocytic leukemia. Leuk Lymph 5:133

  44. 44.

    Juliusson G, Elmhorn-Rosenberg A, Liliemark J (1992) Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 327:1056

  45. 45.

    Delannoy A, Hanique G, Ferrant A (1993) 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine (letter). N Engl J Med 328:812

  46. 46.

    Saven A, Lemon RH, Piro LD (1993) 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. (letter) N Engl J Med 328:812

  47. 47.

    Keating MJ, O'Brien S, Kantarjian H, Robertson LB, Koller C, Beran M, Estey E (1993) Nucleoside analogs in treatment of chronic lymphocytic leukemia. Leuk Lymph 10 [Suppl]:139

  48. 48.

    Tefferi A, Phyliky RL (1992) A clinical update on chronic lymphocytic leukemia. Critical analysis of current chemotherapeutic modalities. Mayo Clin Proc 67:457

  49. 49.

    Hickish T, Serafinowski P, Cunningham D, Oza A, Dorland E, Judson I, Millar BC, Lister TA, Roldan (1993) 2′-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies. Br J Cancer 67:139

  50. 50.

    Vahdat L, Warrel RP (1993) Treatment of acute myeloblastic leukemia in adults with 2-chloro-deoxyadenosine. Proc ASCO 12:991

  51. 51.

    Dimopoulos MA, Kantarjian H, Estey E, O'Brien S, Delasalle K, Keating MJ, Freireich EJ, Alexanian R (1993) Treatment of Waldenström macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med 118:195

  52. 52.

    Dimopoulos MA, Kantarjian HM, Estey EH, Alexanian R (1992) 2-Chlorodeoxyadenosine in the treatment of multiple myeloma. Blood 79:1626

  53. 53.

    Niesvizky R, Siegel D, Michaeli J (1992) 2-Chlorodeoxyadenosine for multiple myeloma. Blood 80:868

Download references

Author information

Correspondence to H. -J. Guchelaar.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Guchelaar, H.-., Richel, D.J. & Schaafsma, M.R. Clinical and toxicological aspects of the antineoplastic drug cladribine: A review. Ann Hematol 69, 223–230 (1994). https://doi.org/10.1007/BF01700276

Download citation

Key words

  • Cladribine
  • Hairy cell leukemia Lymphoid malignancies
  • Drug efficacy
  • Drug toxicity